These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

132 related items for PubMed ID: 11705445

  • 1. Life-threatening hyperkalemia during combined therapy with angiotensin-converting enzyme inhibitors and spironolactone.
    Berry C, McMurray J.
    Am J Med; 2001 Nov; 111(7):587. PubMed ID: 11705445
    [No Abstract] [Full Text] [Related]

  • 2. Life-threatening hyperkalemia during combined therapy with angiotensin-converting enzyme inhibitors and spironolactone: an analysis of 25 cases.
    Schepkens H, Vanholder R, Billiouw JM, Lameire N.
    Am J Med; 2001 Apr 15; 110(6):438-41. PubMed ID: 11331054
    [Abstract] [Full Text] [Related]

  • 3. [Drug-related hyperkalemia resulted from spironolactone and angiotensin converting enzyme inhibitors therapy].
    Dutka M, Dzielski T, Wojciechowska J, Heller L, Trybus M.
    Pol Merkur Lekarski; 1999 Aug 15; 7(38):69-70. PubMed ID: 10522422
    [Abstract] [Full Text] [Related]

  • 4. Syncope caused by hyperkalemia during use of a combined therapy with the angiotensin-converting enzyme inhibitor and spironolactone.
    Erden I, Yalcin S, Ozhan H.
    Kardiol Pol; 2010 Sep 15; 68(9):1043-5; discussion 1046. PubMed ID: 20859899
    [Abstract] [Full Text] [Related]

  • 5. Elderly heart failure patients with drug-induced serious hyperkalemia.
    Vanpee D, Swine CH.
    Aging (Milano); 2000 Aug 15; 12(4):315-9. PubMed ID: 11073352
    [Abstract] [Full Text] [Related]

  • 6. [The 10-minute consultation. Accidental finding: hyperkalemia. Caution with analgesics and bananas].
    Lenz T.
    MMW Fortschr Med; 2005 Jan 27; 147(4):59-60. PubMed ID: 15745346
    [No Abstract] [Full Text] [Related]

  • 7. Spironolactone + ace inhibitor or sartan: risk of hyperkalaemia.
    Prescrire Int; 2004 Apr 27; 13(70):58. PubMed ID: 15148978
    [No Abstract] [Full Text] [Related]

  • 8. Life-threatening hyperkalemia during a combined therapy with the angiotensin receptor blocker candesartan and spironolactone.
    Fujii H, Nakahama H, Yoshihara F, Nakamura S, Inenaga T, Kawano Y.
    Kobe J Med Sci; 2005 Apr 27; 51(1-2):1-6. PubMed ID: 16199929
    [Abstract] [Full Text] [Related]

  • 9. Drug safety in patients with heart failure.
    Juurlink DN, Hansten PD.
    Arch Intern Med; 2005 Jan 10; 165(1):118. PubMed ID: 15642888
    [No Abstract] [Full Text] [Related]

  • 10. Hyperkalemia in ambulant postcardiac surgery patients during combined therapy with angiotensin-converting enzyme inhibitor, spironolactone, and diet rich in potassium: A report of two cases and review of literature.
    Dixit A, Majumdar G, Tewari P.
    Ann Card Anaesth; 2019 Jan 10; 22(2):162-168. PubMed ID: 30971598
    [Abstract] [Full Text] [Related]

  • 11. Life-threatening hyperkalaemia caused by ACE inhibitor and diuretics.
    Jarman PR, Keheley AM, Mather HM.
    Diabet Med; 1997 Sep 10; 14(9):808. PubMed ID: 9300234
    [No Abstract] [Full Text] [Related]

  • 12. [An elderly man with known heart failure admitted with cardiogenic shock].
    Hovland A, Fagerheim AK, Hardersen R, Nielsen EW.
    Tidsskr Nor Laegeforen; 2010 Jul 01; 130(13):1352-4. PubMed ID: 20596117
    [Abstract] [Full Text] [Related]

  • 13. [Late drug-induced hyperkalemia in a patient with congestive heart failure].
    Konopa J, Bułło B, Rutkowski B.
    Przegl Lek; 2005 Jul 01; 62(7):732-3. PubMed ID: 16463712
    [Abstract] [Full Text] [Related]

  • 14. Study warns of danger of combining spironolactone and ACE inhibitors in heart patients.
    Gottlieb S.
    BMJ; 2004 Aug 21; 329(7463):420. PubMed ID: 15321896
    [No Abstract] [Full Text] [Related]

  • 15. Diabetes may be independent risk factor for hyperkalaemia.
    Jarman PR, Mather HM.
    BMJ; 2003 Oct 04; 327(7418):812. PubMed ID: 14525902
    [No Abstract] [Full Text] [Related]

  • 16. [Dangerous hyperkalemia as sequelae of new treatment strategies of heart failure].
    Fuster D, Frey FJ, Ferrari P.
    Praxis (Bern 1994); 2000 Dec 07; 89(49):2073-6. PubMed ID: 11190849
    [Abstract] [Full Text] [Related]

  • 17. Interaction of spironolactone with ACE inhibitors or angiotensin receptor blockers: analysis of 44 cases.
    Wrenger E, Müller R, Moesenthin M, Welte T, Frölich JC, Neumann KH.
    BMJ; 2003 Jul 19; 327(7407):147-9. PubMed ID: 12869459
    [No Abstract] [Full Text] [Related]

  • 18. Tolerability of spironolactone as adjunctive treatment for heart failure in patients over 75 years of age.
    Dinsdale C, Wani M, Steward J, O'Mahony MS.
    Age Ageing; 2005 Jul 19; 34(4):395-8. PubMed ID: 15955761
    [No Abstract] [Full Text] [Related]

  • 19. Serum concentration of potassium in chronic heart failure patients administered spironolactone plus furosemide and either enalapril maleate, losartan potassium or candesartan cilexetil.
    Saito M, Takada M, Hirooka K, Isobe F, Yasumura Y.
    J Clin Pharm Ther; 2005 Dec 19; 30(6):603-10. PubMed ID: 16336294
    [Abstract] [Full Text] [Related]

  • 20. Spironolactone in patients with heart failure.
    Vanpee D, Swine C.
    N Engl J Med; 2000 Jan 13; 342(2):133; author reply 133-4. PubMed ID: 10636753
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.